Literature DB >> 14044602

THE USE OF AZEPINAMIDE IN THE MANAGEMENT OF DIABETES MELLITUS.

A WEINSTEIN, R MASSIE.   

Abstract

Entities:  

Keywords:  ANTIDIABETICS; CHOLANGITIS; HEPATITIS; JAUNDICE; TOLBUTAMIDE; TOXICOLOGIC REPORT

Mesh:

Substances:

Year:  1962        PMID: 14044602      PMCID: PMC2249067     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


× No keyword cloud information.
  8 in total

1.  Clinical evaluation of a new hypoglycemic sulfonylurea, tolazamide. A preliminary report on its chlorinated analogue, azepinamide.

Authors:  W A ABELOVE; R ECHENIQUE; A G HILLS
Journal:  Diabetes       Date:  1962 May-Jun       Impact factor: 9.461

2.  Present-day management of diabetes.

Authors:  G G DUNCAN
Journal:  R I Med J       Date:  1961-09

3.  Incidence and causes of secondary failure in treatment with tolbutamide. Experience with 2,500 patients treated up to five years.

Authors:  R A CAMERINI-DAVALOS; A MARBLE
Journal:  JAMA       Date:  1962-07-07       Impact factor: 56.272

4.  Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus.

Authors:  S S FAJANS; J W CONN
Journal:  Diabetes       Date:  1960 Mar-Apr       Impact factor: 9.461

5.  The effects of tolbutamide and chlorpropamide on patients exhibiting jaundice as a result of previous chlorpropamide therapy.

Authors:  L H HAMFF; H A FERRIS; E C EVANS; H W WHITEMAN
Journal:  Ann N Y Acad Sci       Date:  1959-03-30       Impact factor: 5.691

6.  Allergy to chlorpromazine manifested by jaundice.

Authors:  L E HOLLISTER
Journal:  Am J Med       Date:  1957-12       Impact factor: 4.965

7.  Resolution of chlorpromazine jaundice without withdrawal of the drug.

Authors:  W H TRETHOWAN; J W SHAND
Journal:  Med J Aust       Date:  1958-04-26       Impact factor: 7.738

8.  Acetohexamide. Preliminary report on a new oral hypoglycemic agent.

Authors:  G E MAHA; W R KIRTLEY; M A ROOT; R C ANDERSON
Journal:  Diabetes       Date:  1962 Mar-Apr       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.